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S~m~a.ry. - 15 new C/Si-analogue pairs (C-compounds and sila- or disila-substituted derivatives, respectively), which are structurally related to 
mfedlpme, have been synthesized. These and some further C/Si-pairs have been investigated comparatively with respect to their physicochemical 
and pharmacological properties. Using reversed-phase thin-layer chromatography it was shown that both the sila- and disila-analogues are more 
Iipophilic than the corresponding C-compounds. With respect to the in vitra spasmolytic potencies the Si-compounds show approximately similar 
structure-activity relationships to their carba-analogues. However, in some cases marked differences in in vivo effects (cardiovascular and anti-
hypertensive activity) could be demonstrated. 
Resume. - La synthese de lS nouvelles paires d'analogues C/Si (composes carbones et composes mono- ou disilicies-substitues), derivant de la 
structure de la nifectipine, est decrite. Une etude comparative de leurs proprietes physico-chimiques et pharmacologiques, y inclus quelques autres 
paires d'analogues C/Si a structure semblable, a ete effectue~; La chromatographie en couche mince aphases inversees a montre que les composes 
silleies sont plus lipophiles que les composes carbones corre~pondants. En ce qui concerne leurs proprietes spasmolytiques in vitra, les composes 
silicies sont caracterises par des relations structure-activite sllmblables a celles des analogues carbones. Au contraire, la comparaison In viva (activite 
cardiovasculaire et antihypertensive) amis en evidence, dans quelques cas, des effets pharmacologiques de substitution C/Si tres prononces. 
Zusammenfassung. - IS neue C/Si-Analogenpaare (C-Verbindungen und sila- bzw. disila-substituierte Derivate), die sich strukturell vom Nifedipin 
ableiten, wurden synthetisiert. Diese und einige weitere C/Si-Paare wurden hinsichtlich ihrer physikochemischen und pharmakologischen Eigen-
schaften vergleichend untersucht. Mittels reversed-phase-Dünnschichtchromatographie wurde gezeigt, daß die Sila- bzw. Disila-Analoga lipophiler 
sind als die entsprechenden C-Verbindungen. Bezüglich der spasmolytischen in vitra-Aktivitäten zeigen die Si-Verbindungen in erster Näherung 
ähnliche Struktur-Wirkungs-Beziehungen wie ihre Carba-Analoga. Dagegen konnten hinsichtlich der ill vlva-Effekte (cardiovasculäre und anti-
hypertensive Aktivität) in einigen Fällen große Unterschiede nachgewiesen werden. 
Key-words : Sila-substitution of drugs. - Nifedipine-Iike CjSi pairs. - Spasmolytic, antihypertensive and cardiovascular activity. - Structure-
activity relationships. - Lipophilicity. - RM-values. 
INTRODUCfION 
In recent years several rughly potent dialkyl 4-aryl-l,4-
dihydropyridine-3,5-dicarboxylates have become known, 
which inhibit the contractility of vascular smooth muscle. 
Compounds la (nifedipine, BAY a 1040) (2-12), lb (nilu-
dipine, BAY a 7168) (11, 13), le (nimodipine, BAY e 9736) 
(14-16), ld (SKF 24260) (17, 18), le (FR 1:534) (19), If 
(nicardipine, YC 93) (20), 19 (nisoldipine, BAY k 5552) 
(21), and Ih (nitrendipine, BAY e 5009) (22) are particularly 
active examples of this substance class. Nifedipine is al ready 
used in the treatment of ischemic heart disease. 
Pharmacological investigations of a number of dialkyl 
2,6-dimethyl- 4-aryl-l ,4- dihydropyridine- 3,5- dicarboxylates 
(.) Some results have been described previously : R. Tacke, A. 
BentJage, R. Towart, and W. Vater, D.O.S. 2 837 477 (13.3.1980) ; 
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1981. 
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have shown that the alkyl ester groups in the 3,5-positions 
of the 1,4-dihydropyridine ring influence the pharmaco-
dynamic and pharmacokinetic properties of these compou~ds 
substantially (22, 23). In the course of our work on « slla-
pharmaca », it was feIt to be of i~terest to inves~igate th.e 
physicochemical and pharmacologlCal ~ffe~ts. of ~Jla-subst~­
tution in the alkyl ester groups of mfedlpme-hke 1,4-dl-
hydropyridines. In two preceding communications (I, 24) 
we have reported the synthesis and properties of the corn-
pounds 13a/13b/13c and 14a/14~. The p~e~ent w~rk .de-
scribes tbe synthesis of the 1,4-dlhydropyndme denvatlves 
8a/Sb - 12a/12b and 15a/lSb - 24a/24b (15 new CjSi-pa!rs) 
as weIl as the lipophilic properties and some pharrnacologlcal 
effects of 8a/8b - 24a/24b and 13c. Compounds 18a and 
18b are closely structurally related to nisoldipine (lg), and 
moreover can be regarded as respectively t-butyl- and 
(trimethylsilyl)-substituted derivatives of nifedipine (la). 
A very pronounced structural similarity also exists between 
the pair 22a/22b and nimodipine (lc). 
CHEMlSTRY 
The synthesis of the symmetrically 3,5-substituted 1,4-
dihydl'opyridine derivatives 8a/Sb - 12a/12b and 15a/15b 
was achieved analogously to the preparation of 13a/13b 
and 14a/14b (cf. lit. (24» by the reaction of an aldehyde 
R-CHO with the twofold molar amount of the appropriate 
alkyl acetoacetate 4a, 4b, 5a, and Sb, respectively, and an 
excess of ammonia. 
8a/Sb -15a/15b 
EI n R EI n R 
8a C C6H5 12a C 2-pyrldyl 
8b SI CsH5 12b SI 2-pyrldyl 
9a C 1 3-CI-CsH4 13a C 1 3-NOz-CsH4 
9b Si 1 3-CI-C6H4 13b SI 1 3-N02-C6H4 
10a C , 2-CI-C6H4 14a C 1 2-NOz-C6H4 
lOb Si , 2-CI-CsH4 14b Si 1 2-NOz-CsH4 
11a C , 3-pyrldyl 15a C 2 3-NOz-C6H4 
11b SI 1 3-pyrldyl 15b SI 2 3-NOz-C6H4 
The 3,5-unsymmetrically substituted 1,4-dihydropyridine 
derivatives 16a/l6b - 24a/24b were synthesized analogously 
to 13c (cf. lit. (1) and lit. (25) ) by the reaction of tbe appro-
priate alkyl ß-aminocrotonates 6a, 6b, 7a, and 7b, respec-
tively, with a 2-aralkylidene-acetoacetate of the type 
R2C6H4-CH=C(COCH3)COOR1. 
Tbe starting materials 4a, 4b, 5a, and Sb were prepared 
in accordance with known methods by the addition of 
diketene to the appropriate alcohols 2a, 2b, 3a and 3b, 
respectively, in the presence of a small quantity triethyl-
amine. By furtber reaction with ammonia under catalysis 
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13c. 16a/16b - 24a/24b 
EI n Rl n" LI n nl R? 
13c Si CHzC(CH313 3-NO:! 20b Gi 1 CH(CHJ)2 3-N02 
16a C CH3 4-NO:! 210 C 1 CH2-C ·CH 3-NOz 
16b Si CH3 4-NOz 21b Si 1 CH2-C~CH 3-N02 
17a C CH3 3-N02 228 C 1 CH2CHzOCHJ 3-NOz 
llb SI 1 CH3 3-NOz 22b 5, 1 CHzCHzOCH3 3-N02 
18a C CH3 2-NOz 238 C 2 CH3 3-NOz 
1Bb Si CH3 2-N02 23b 5, 2 CH3 3-N02 
19a C , C2HS 3-N02 248 C 1 ~Hs 2-CI 
19b Si 1 C2HS 3-N02 24b SI 1 C2HS 2-CI 
20a C , CH(CHa)2 3-N02 
of p-toluene sulfonic acid the alkyl ß-aminocrotonates ~a, 
6b, 7a and 7b respectively, may be synthesized. of WhlCh 
6a and 6b have been previously described by us (24). 
2a/2b,30/3b 4a14b,5a/5b 
2, 4, 6 a b 
EI C Si 
n 1 1 
3, 5, 7 a b o NH2 
11 I 
EI C SI (CH3)3 EI (CH2)n-O-C-CH=G-CH3 
n 2 2 6a/Sb, 7aflb 
The structures of the new l,4-dihydropyridines 8a/8b-
12a/12b and 15a/15b - 24a/24b were confirmed by analyses 
(Table 1 and 2, respectively) and spectroscopic measurements 
(1 H NMR and mass spectroscopy). In aH cases the molecular 
ions M + could be established in the mass spectra. The 
1 H NMR spectra are relatively simple and reflect weH the 
various structural elements of the compounds. The NMR 
data of 3 CjSi-pairs are listed in Table 3 as typical examples. 
LIPOPHILIC PARAMETERS 
Lipophilic parameters are of particular importance in 
the investigation of quantitative structure-activity relation-
ships of nifedipine analogues (26). The lipophilicity of the 
compounds 8a/Sb - 24a/24b and 13c (Table 4) was measured, 
because substituent constants for a sila-substitution are not 
known. Instead of the laborious measurement of octanol/ 
water partition coefficients (log P) we measured the RM-
R. TACKE 
TABLE I. . - Dialkyl 2,6-dimethyl-4-aryl-l,4-dihydropyridine-3,S-
dicarboxylates Sa/Sb - 12a/lZb and lSa/lSb 
No Compound Fonnulaßl YIoId" Mp.CI Analysoslcalcd./tound) ('0) 
(mol moas) r.) ('C) C H N SI 
OlneopenlyI2.6-d1methyl-4-phonyl- C,.H,,,NO. 48 149 1281 853 3.39 8. 1.4 -dlhydropvndIOO- 3,5-dlcDrboxy' 141361 1/1) 122 8.6 35 laie 
BIS Iinmeihyls.lyl-methyl) 2,6 .. dl- C"H,.NO.S~ 46 123 81.98 1.91 3.14 12.60 8b melhyl-4 -phenyl-l.4 .. dlhydropyndlne- (4457) (A) 821 8.0 3.2 12.5 3.5-dlc6I'boxyI810 
DlnoopenlyI2.6-dlll\elhyl-4-13-chlo- C,.H:J,CINO. 41 IB9 61.03 1.65 3.13 
90 rophenylI-l.4-dlhycJropyndlne .. 3,5- 1448.0) lAI 66.8 1.6 3.1 dlcarboxylate 
B,sllromelhylallyl-molhyl) 2.6-dl· ~)H34CtNO.Sll 41 129 5153 1.14 2.92 11.10 9b melhyl-4-13-chIOtophenYIl-l.4-d,. 1480.11 IAl 575 1.2 3.0 11.9 hydropyndlne-3.6-dlcarboxylalo 
DineopenlyI2.6-chm81hyl-4-12-chlo~ C,.H"CINO. 82 187 6703 1.65 3.13 
100 rophenyll-l,4-dlhydropyndine-3.5_ 1448.01 IBI 668 7.1 3.2 dlcarboltylate 
BisUnmelhyISllyi-methyl) ?Ii-dl· C"H340NO.Siz 46 129 57.53 7.14 2.92 11.70 lOb molhyJ..4-(2-chlorophOl.\1)-1.4-<11. (4801) lAI 57.5 7.2 3.0 11.6 
hydropYlldlne-3.S-dlcarboxylale 
OineopenlyI 2.6-dlmolhyl-4-(3_py_ C'4H34~04 68 112 6954 827 6.76 110 rldyl)-1A-dihydropyridlne-3.5-dl- (414.5) (B) 69.5 8.2 6.7 
carbollylale 
Bls(tnmethylsllyl-methyl) 2.6-d1- ~1H3-tN,O.SI" 88 162 5916 761 6.21 12.51 
11 b melhyl-4-(3-pyndyll-l.4-<1lhydro· (4461) IDl 591 11 62 127 
pyndlne-3.5-dlcsrboxylale 
Dlneoponlyl 2.6-<1lmelhyl-4-12-py· C ... H3.N,O. 41 223'" 6954 8.21 6.16 121 ndyl)-1.4-dlhydropyOdlnc-3.5-d,- 141451 (BI 694 8.3 6.5 
cBrboxylale 
B,sllnmeihylSlIyI-molhyD 2.6-<11' C11Hl4N,O.SI, eo 205 5916 161 6.21 1257 
12b melhyl-4.(2-pyndyl)-I,4-dlhydro. (448.1) (CI 590 16 63 124 
pyndlne-3.S-dICarbo)(yfolo 
BI&(3.3-dlmolhyl-bulyl) 2.G-dlmelhyl- C"H,.N,o. 67 120 6664 7 81 5 76 
15. 4-(3-n1tropllunyl)-1.4-dlhydropyn- (486.6) 101 665 1.0 58 dlne~3.5-dlcar\)oxyJQle 
BIG(2-tnmolhylsllyl-elhyl, 2.6-di- C,!.HlsNz0 6Sl? 42 120 57.88 738 540 1083 
15b melhyl-4- (3- n1trophenyl)-I.4-dlhy- (518.8) (01 Ze.l 1.01 5.3 110 
dropyndlflc .. 3,S .. d,carbo)(y1ato 
1\) The molecular masses of all compounds were established by 
mass speclroscopy. 
b) The yields are related to recrystallized products and have not 
been optimized in most cases. 
C) Average values of several measurements. The recrystaIlisation 
solvent is given in parantheses : A ether/petroleum ether, B ethanol/ 
ether/petroleum ether (only a small amount of ethanol as dissolving 













0.7 0.8 I • 0.9 RM (C) 
RM (Si)" 0.128 (± 0.048) + 0.917 (± 0.076) R~ (C) 
n = 10 F= 143.98 P <0.0001 T= 11.99 r =0.95 
FIG. 1. - Plot of equation (I) showing the linear dependence of 
RM(S:) an:! RM(C). 
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TABLE. Ir - Dialkyl 2,6-dimethyl-4-aryl-J,4-dihydropyridine-3,S-
dicarboxylates 16a/16b - 24a/24b 
No Compounu Formula
ill YlcldO' MpC' Analyses (calcd Ifoundl (0_1 
(mol mass) r,) ('Cl C H N SI 
161 M.lh~1 noopenlyI2.6-dlmelhyl-4-14- C"H,sN,o. 10 157 6267 651 696 
nUrophen)'l)-l." .. dihydropyridine- (402.4) lAI 621 57 70 
3.5-dicarboxytate 
16b Melhyllnmelhylsllyl-melhyI2.6-<11· Cz0H2,N,OaSI 58 137 5740 6.26 669 611 
melhyl-4-(4-nilrophOnyl)-I.4-dlhy· (41851 lAI 589 63 6.8 66 
dropyndtne-3,5-dlcarboxYlato 
17. Melhyl neopenly/ 2.6-dimolhyl-4-(3- C"H"N,O. 11 136 ~267 6.51 6.96 
nitrophenyl)-1,4-dihydropyridina- 14024) IB) 823 68 70 
3,5-chca-bolCylate 
l1b Methyl tri1lethylsllyl-methyt 2.6-dl. C",H,sN,o,SI 67 120 5140 6.26 6.69 6.71 
methyl-4-(3-nitrophonyl)-1.4-dihy· (418.5) (BI 514 62 67 69 
dropyridlne-3.5-dicarbOXYlale 
180 Melhyl neopenlyl 2.6-dlmolhyH-I2- Ct,Hz6NlOe 39 113 6261 651 6.96 
nilrophenyQ-l,4-dihydropyrldlne- (402.4) IBI 625 61 68 3.5-dlcarboxylale 
18b Methyl tnmelhyI8lIyl-methy12.6-di- C,oH,.N,O.SI 69 156 5140 6.26 6.69 6.71 
melhyl-4-(2-nilrophenyl)-1.4-dJhy· 1418.5) (C) 57.2 63 67 6.8 
dropyridino-3.5-dicarbox.ylate 
190 Ethyl neopenlyI2,6-dimethyl-4 .. (3- CzaHZ8N20S 62 138 6345 6.78 6.13 
nllroph.nyl)-1.4-<1lhydropy~dlno- 1416.5) 10) 63.4 68 6.1 
3.5-<1lcarbOxvlall 
19b ElhyllrimC'lhyl311yJ-mclhy' 2.6-d1- C"H,.N,o.S, 55 115 58.31 6.52 6.48 649 
:r,e!:~id1~!:3~~~rc~~~~~~;dIhY' (432.5) (01 56.1 65 66 62 
20. lsopropyl noopentyl 2.6-dlmelhyl-4- C"H3DN,O. 67 153 64.11 70. 6.51 
i3-nllrophenYQ-l,4-dihydropyridlne- (430.5) (BI 643 10 64 
3.5-dlcarboxylale 
20b ~~:~h~t~'!.'(1~~~~~~~~~W~f.f~ihY· '4:HlON:OsSI 65 121 59.17 611 6.21 6.29 (446.61 ICI 592 61 6.3 6.2 
dropyridlne-3.5-dlcarboxylete 
21. Propin-3-yl ncopentyI2.S-dimethyl- ~3H:!6N206 83 141 64.78 6.14 651 
4-(3-nilrophenyl) .. 1.4-dlhydropyri. (426.5) (0) 64.8 62 6.3 dlne-3.5-dicarboxylalo 
21b Propln-3-yl trlmethylsltyl-melhyl C"H"N,o,Si 61 148 5911 592 6 33 635 
2.6-dimelhyl-4-(3.,..nilrophenyl)-1.4- (442.51 101 597 61 6.5 65 dihydropyridlnc-3,5-dlcarboxykalo 
22. (2-Molhoxy-elhyl) nCopenlyI2.6-dl· C2"HJoN20, 57 124 6187 677 6.21 
mOlhYI-4-(3-nitrophenyl)-1.4-dthy- (446.5) (01 615 81 64 
dropyndine-3.5-dIco:boxylale 
22b (2-Metholl:y-elhyl) IrimethWadyt·mo- C"H",N,O,S> 83 92 5112 654 606 6 07 
IhyI2.6-dimelhyl-4-(3-niJrophony!)- (482.61 lAI 572 66 5.9 59 
1,4-dihydropyrldlno-3.5-dicarboxylate 
23. MethyI13.3-<1lmelhy!-lJ\llyl) 2.8-<11· C"H,eN,Oe 75 97-100'" 6345 618 6.73 
melhyl-4-(3-nftrophonyl)-1.4-dihy· 1416.51 (0) 633 68 6.9 
dropyridine-3.5-dlcarbox'ltatD 
23b Melhyl (2-trimelhylsllyl-Blhyll C2IHlBN~eSI 69 125 5831 652 6.46 
2.6-dimethyJ-4-(3-nitrophenyl)-1.4- 1432.5) (01 580 65 67 dlhydropyrldine-3.5-dlcarlloxylole 
24. Elhyl noopenlyI2.6-dlmelhyl-4-12- CZ;:-H28CJNO .. 40 176 .. ' 79 t11 8510 695 345 
chlorophenyl)-l.4-dihydropyrtdlnc- (405.91 (BI 648 70 35 3.5-d6carbOxYI8Ie 
24b Elhyll'lmelhylsllyl-melhyI2.6-dl. C"Ii~'CINO'Sil 25 119-130" 6977 6.69 332 
melhyl-4-(2-chlorophonyll-1.4-dlhy· 142201 IBI 598 67 33 
dropyrldine-3.5-dicarboKylato 
1» The molecular masses of aJl compounds were established by 
mass spectroscopy. 
b) The yields are related to recrystallized products and have not 
been optimized in most cases. 
c) Average va)ues of several measurements. The recrystallisation 
solvent is given in parantheses : A methanol, B ethanol/ether/petroleum 
ether (on)y a small amount of ethanol as dissolving mediator), C ethanol/ 
ether, D ethanol (96 %). 
11) The measurements were performed with a Kofler melting point 
apparatus. 
va lues (see experimental section). The RM-values of the sila-
compounds were then correlated with those of the corres-
ponding C-compounds, resulting in a significant correlation 
for the exchange of one carbon atom by one silicon atom 
[equation (1), Fig. 1] as weil as for the replacement of two 
carbon atoms by two silicon atoms [equation (2), Fig. 2]. 
RM(Si) = 0.128 (± 0.048) + 0.917 (± 0.076) RM(C) (1) 
n = 10, F = 143.98, P < 0.0001, T = 11.99, r2 = 0.95 
RM(2 Si) = 0.091 (± 0.054) + 1.060 (± 0.064) RM(C) (2) 
n = 8, F = 278.68, P < 0.0001, T = 16.69, r 2 = 0.98 
The validity of the regression was co~fi~.med ?y t~e 
following statistical criteria : standard deVIation (glven m 
brackets) F-test value (F), level of significance (P), T-test 
value (T), and squared correlation coefficient (r2). 
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TABLE III _ 1H NMR spectroscopic data B) 0/8a/Sb, 18a/18b, and 
22a/22b. 
>c-C-CH, o-CH, o-CHt-SI o-CH,-C C(4)-H N-Hbl """"atH No. St-CH., c-CHo 
3.72 3.83 6.14 e.o. 7.0.-7.4 0.94 2.35 
----- --.. -
AB quartel. 4 H 
.. IH .. IH m.5H 8. 
--- .. 18H ..6H J-lIHz 
3.76 6.0.7 8.0. 7.Q..7.4 0..0.5 2.35 
----- --- .. IH •• IH m.SH ab 
.. 18H --- .. eH .. 4H 
2.33 3.59 3.82 5.77 6.0. 7.1-7.8 0.81 2.29 -_ .... 
'.2H •• IH •• 1H m.4H 1h .. ---
"eH •• 3H •• 3H s.3H 
2.33 3.57 3.79 5.75 6.1 1.1-7.8 0.05 2.29 ...... ---
•. IH •• IH m.4H 18b 
.. 9H -_ .. - •• 3H •• 3H 1.3H •. 2H 
2.34 2.42 3.38 cl dl 5.19 8.0. 7.3-8.2 0..88 
---- •• IH •• IH m.4H 22. .. -.... -
.. 9H •• 3H ..3H .. 3H 
2.33 2.39 3.36 3.70. 5.14 6.2 7.3-82 0.03 .1 
.. 1i'i •. 1H m.4H 22b 
'.9H - 1.3H •• 3H .. 3H •• 2H 
a) Solvent CDCI3 , internal standard CHCI3 (87.27 ppm) .. Chemi~1 
shifts are presented in 8 units (ppm), followed by the respecttve multl-
plicities and relative intensities. 
b) Broadened resonance signal. . 
e) OCHs C : Singlet (1. approximation? ~t 3.73 (~H). It IS probable 
that this is an AB-system, whose analysIs IS comphcated by an over-
lapping with the OCHsCHs O-resonance. 
d) OCHs CH2- 0 : AA'BB'-system, centres of the multiplets at 
3.58 (2 H) and 4.19 (2 H). 
c) OCHs CH,O : AA'BB'-system, centres of the multiplets at 
3.60 (2 H) and 4.20 (2 H). 
T ABLE IV. - RM-values a) 0/ 8a/8b - 13a/13b, 13c, and 14a/14b -
llta/24b. 
Compound 1\1 Fl,.i Compound RM RM 
No. me8sured calculaled difference No. measured C8lculaled dlflerence 
8a 0.86 16b 0.67 0.62 -0.05 
8b 1.00 1.00 0.0 17 a 0.54 
98 0.91 17b 0.66 0.62 -0.04 
9b 1.08 1.06 -0.02 18a 0.44 
108 0.92 18b 0.52 0.53 0.01 
10b 1.07 1.07 0.0 19a 0.67 
118 0.57 19b 0.73 0.76 0.03 
11 b 0.68 0.7 o.o~ 20a 0.69 
128 0.69 20b 0.73 0.74 0.D1 
l2b 0.75 0.72 -0.03 218 0.56 
138 0.88 21 b 0.62 0.64 0.02 
13b 0.99 1.02 0.03 228 0049 
l3C 0.93 0.93 0.0 22b 0.54 0.58 0.04 
148 0.90 23a 0.71 
l4b 1.01 1.05 0.04 23b 0.6 0.76 -0.02 
150 1.07 248 0.69 
15b 1.25 1.23 -0.03 24b 0.77 0.76 -0.01 
16a 0.54 
a) RM measured: calculated by means of the experimental RF-values 
and the formula RM = log U/RF - 1] ; 
RM calculated : calculated by means of equation (1) and equation (2), respectively. 
From equations (1) and (2), it ean be eoncluded that the 
Si-compounds are .more lipophilic than the analogous 
C-compounds. These results are at first surprising, as one 
would expect an increase in polarity (and thus a reduced 
Iipophilicity) by sila-substitution, owing to the different 
electronegativities of carbon and silicon (Allred-Rochow : 
Xc = 2.50, XsI = 1.74). However, these apparently contra-
dictory results may be explained by tbe fact that tbe 
(CH3hSiCH 2 group has a greater space flUing effect than 
the eorresponding (CH3hCCH2 unit, and thus presents a 
greater lipophilic surface area. Tbe sila-analogues described 




















RM (2 SI) =0 091 (± 0.054) + 1.060 (±0.064) RM (C) 
n - 8 F"'" 278.68 P< 0.0001 T'" 16.69 r2 - 0.98 
Fla. 2. - Plot of equation (2) showing the linear dependence of 
RM(2Si) and RM(C). 
here are therefore capable of stronger interactions with 
the lipid phase. . 
Similar results have been reported by Woo et al. for some 
sila-substituted barbiturates (27). 
From the RM-values of the C/Si pairs shown in Table 4, 
a mean increase in lipophilicity ö'RM = 0.07 for the replace-
ment of one carbon atom by one silicon atom can be 
calculated. At present additional experiments .are under 
way to see how far this fragment constant descrJbed above 
may be applicable to co.mpounds of other chemical structures. 
PHARMACOLOGY 
The spasmolytic properties of 8a/Sb - 24a/24b ~nd 13c 
were investigated in vitro on the Ba + + -stimulated Isolated 
guinea pig ileum. In vivo selected compounds were ~ested 
with respect to their cardiovascular effects (increase m. ~e 
coronary sinus oxygen content in the dog after Lv. adml~ls­
tration), aod to their antihypertensive activity (reductlOn 
in the blood pressure on the renal-hypertensive rat a~ter 
p.O. administration). The results of these pharmacolog1ca1 
investigations are given in Table 5. 
Discussion 0/ the structure-activity re/ationships. 
The qualitative structure-activity relationships, which 
derive from the screening data given in Table 5, conflrm 
the results of previouß studies carried out in the fi~ld of 
dialkyl 2, 6-dimethyl-4-aryl-l ,4-dihydropyridine-3. 5-dlcarb-
oxylates (co.mpare for example lit. (22) and lit. (23». QSAR-
analyses were performed by the use of .multiple regression 
R. TACKE 
TABLE V. - Phurtllllm/tI.r:;('(J1 pl'(/!lt'r(jes !Lob) 0/ Sa/Sb - 13a/13b, 
J3c. 14a/ J4b - 24n/24b. alld lIi/edlp;/lC! 
Compound Spasmolytte olfoet
Cl CardloVClscular eUeet"' Antlhypertenslve eUectO' 
No. (guinea plg. In vllro) (anaesthetlzed dog. (renal-hypertenslve rot. 
IDso[mollll I. v. Cldmlnlstratlon) po. administration) 
Ba 5 I( 10-7 + 
-----8b ::I I( 10" + 
-----
9a 51( 10" ++ ----
9b 7 I( 10" ++ 
-----
10a I x 10" + -----
lOb 7 x 10-8 ++ -----
11a :;.. 1 x 10-6 
----- -----
11 b >I x 10-6 
----- ----
12a >1 x 10-6 + -----
12b > 1 I( 10-6 + ----
13a el( 10-9 ++ >100mg/kg 
13b 2 x 10-8 + IOOmglkg 
13e 6 x 10-9 +++ 10mg/kg 
14a 4 x 10-8 + >100mg/kg 
14b 6 x 10-8 ++ > 100 mg/kg 
ISa 5 x 10-1 + > 100 mg/kg 
lSb 5 x 10-7 + > 100mg/kg 
ISa I X 10-7 ++ -----
1Gb I Je 10-1 + -----
171 2 Je 10-9 ++++ 1 mg/kg 
17b 1 x 10-8 +++ -----
18a 2 x 10-9 ++++ 1 mg/kg 
18b 3 I( 10-8 ++++ 1 mg/kg 
191 3x 10-9 ++++ 3 mg/kg 
19b 4 x 10-9 ++++ -----
200 1 Je 10-9 ++++ -----
20b 2 x 10-8 +++ ----
218 5 x 10-9 ++++ --_ ... -
21b 8 x 10-9 ++++ ----
228 8 X 10-9 ++++ ----
22b 1 x 10-9 ++++ -----
238 5x 10-8 ++ -----
23b 5 x 10-8 ++ -----
248 5x 10-8 ++++ ----
24b 5 x 10-6 +++ -----
nlfedlplne l.4x 10-8 ++++ 0.1 mg/kg 
IL) Pharmacological screening data. - b) The values for 13a/13b/13c, 
14a/14b and nifedipine are taken from lit. (24). - c) The activity is 
defined by the dose (1060)' which leads to 50 % inhibition of a Ba++-
!nduced contraction of the isolated guinea pig ileum. - <I) The acti~ity 
!s defined by the dose, which leads to an increase of the 0a-saturatlon 
10 the coronary sinus blood of at least 20 % : + > 0.5 mg/kg, -I- + 
~ 0.5 mg/kg, -I- + + .,;; 0.05 mg/kg, + + + + C;;; 0.01 mg/kg. The 
~easurement was performed 1 h after administration. - 0) The activity 
IS defined by the minimum dose which leads to a decrease of the blood 
pressure of the renal-hypertensive rat of at least IS mm Hg. 
analysis employing steric, electronic and Iipopbilic para-
meters, but no significant correlations were observed for 
the test substances in tbeir entirety. Tbe following trends 
may, bowever, be seen for sub-groups : in tbe series of tbe 
symmetrically 3,S-substituted 1,4-dibydropyridines 8a/8b " 
ISa/lSb the 4-(pyridyl) compounds 11a, llb, 12a and 12b 
as weil as the 4-phenyl derivatives 8a and 8b are all of 
low activity. Similar potencies were found for tbe 4-(chloro-
phenyl) compounds 9a, 9b, 10a and lOb. Tbe introduction 
of 4-(nitrophenyl) substituents (1311, 13b, 14a and 14b) 
leads to a significant increase of the in vitro activity, which 
is comparable with that of nifedipine. However, elongation 
of both alkyl groups in 1311 and 13b by a CH2 group (-+ ISa and 15b, resp.) decreases the potency. In contrast 
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to the similar in vitro activity of 13a, 13b, 14a, 14b, and 
nifedipine, these compounds differ substantially in their 
in vivo effects : nifedipine was found to be ,....., 1 - 3 orders 
of magnitude more potent than its bulkier substituted 
derivatives 13a, 13b, 14a and 14b. 
Tbe asymmetrically 3,S-substituted 1,4-dihydropyridines 
16a/l6b - 24a/24b and 13c are, mutatis mutandis, clearly 
more potent than the symmetrically substituted compounds. 
In this series also a decrease of activity was observed when 
making the alkyl ester groups bulkier (compare 17a and 
17b with 23a and 23b, resp.)_ In the series of the 4-(nitro-
phenyl)-1,4-dihydropyridines 16a, 16b, 17a, 17b, 18a and 
18b the 4'-nitro derivatives 16a and 16b are of low activity, 
whereas the corresponding 2'- und 3' -nitro compounds 
l7a, l7b, 18a and 18b are of 1 - 2 orders of magnitude 
more potent and reach the activity of nifedipine (in vitro 
and in vivo). 
Although the potency of some of the compounds described 
may approach or even exceed that of nifedipine in vitro 
or in vivo after i. v. administration (anaesthetized dog) the 
activity after p.o. administration (renal hypertensive rat) 
is in general inferior, probably due to the pharmacokinetics. 
From the data given in Table 5 it is obvious that tbe 1,4-
dibydropyridine derivatives 8a - 24a in general exhibit 
similar qualitative structure-activity relationships (in vitro) 
as tbeir sila-analogues 8b - 24b : the replacement of one 
or two carbon atoms in the alkyl ester groups by one or 
two silicon atoms seerns not to change the order of magni-
tude of the spasmolytic activity. The differences found for 
tbe pairs 17a/I7b, 18a/18b and 20a/20b bave to be regarded 
witb reservation (preliminary screening data) and require 
further investigations. However, in principle small but 
significant differences between C/Si-analogues are conceiv-
able as shown for the tripie 13a/13b/13c (cf. lit. (24). 
Witb respect to tbe in vivo activity, the sila-substitution 
effects in general may be more pron::>unced because of a 
different behaviour of the analogues concerning absorption, 
distribution, rnetabolis.m, and excretion. For example, 
careful investigations have shown that tbe cornpounds 
13a, 13b and 13c in spite of tbeir similar in vitro activity 
differ substantially in vivo in their antihypertensive potency 
(24). 
The significantly increased lipopbilicity caused by the 
C/Si-exchange in the alkyl ester groups of tbe 1,4-dihydro-
pyridines tested here seems to be tao small to inftuence the 
biological activity in adefinite manner : so far no corre-
lations between these physicochemicaI aIterations and the 




Melting points were determined on a Mettler FPI apparatus. IH 
NMR spectra were obtained with a Bruker HFX-90 spectrometer. 
Mass spectra were recorded on an AEI-MS-9 instrument at 70 eV. 
Neopelltyl alcohol 2a and 3, 3-d;methyl-I-butallol 3a were commer-
cially available. (Hydroxymethyl)trimethylsi!ane. 2b ~nd (2-hydl'ox~­
ethyl)tl';methylsilalle 3b were prepared accordmg 111. 28 and ht. 
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(29), respectively. Neopel1lyl acetoacetate 4a and trimetllylsilyl-
methyl acetoacetate 4b were prepare'd according Ut. (24). 
3,3-Dimethyl-butyl acetoacetate Sa. 8.41 g (0.1 mol) dlketene are 
added dropwise with stirring to 10.22'g (0.1 mol) 3b and 0.1 mL trietbyl-
amine at 90°C, so that tbe temperatqre of tbe reaetion mixture remains 
at 85-9S·C witbout further heating· (Na almospbere). The mixture is 
subsequently stirred for a further 2 h at 90°C and then disti1led under 
vaeuum over a Vigreux eolumn. Yield 16.0 g (86 %) of a colourless 
IH-NMR-speclroscopic pure liquid. The product is redistilled for 
analytical purposes. Bp. 65-69°C/0.9 mm Oit. (30) : bp. 223-225°C/ 
760 mm, 108-110.5 DC/ll mm). - lH NMR (CDCla) : 80.93 (5,9 H, 
C-CHJ, 1.56 (m, centre of the AN-part of an AA'XX'-system, 2 H, 
C-CHa-C), 1.94 (<< s », )c = t-CHs , enol form) and 2.27 (s, CO-
CHs , keto form) with a relative total intensity corresponding to 3 H, 
3.43 (5, CO-CH2-CO, keto form), 4.19 (m, centre of the XX'-part of 
an AA'XX'-system, 2 H, C-CHa-O), 4.96 (<< s », -CH = c(, enol 
form), OH-resonance could not be observed. - Mass speetroscopy : 
m/e(M+) => 186. C 1oH 180 a (186.3). Calcd. : C 64.49 H 9.74, Found : 
C 63.9 H 9.6. 
2-Trimethylsilyl-ethyl acetoacetate Sb. Analogous to the preparation 
of Sa by the reaction of 70.95 g (0.6 mol) 3b witb 50.44 g (0.6 mol) 
diketene in the presence of 0.5 mL triethylamine. Yield 94.2 g 
(77.61 X), bp. 58-61°C/0.3 mm (Ht. (31) : bp. 77-80·C/l mm). 
- lH NMR (CnCla) : /) 0.03 (s, 9 H, Si-CHs), 0.99 (m, centre 
of the AN-part of an AA'XX'-system, 2 H, Si-CHa-C), l.92 (<< s », 
) C· = t-CHa , enol form) and 2.24 (s, CO-CHa , keto form) with a 
relative total intensity corresponding to 3 H, 3.40 (5, CO-CHa-CO, 
keto form), 4.20 (m, centre of the XX'-part of an AA'XX'-system, 
2 H, C-CHa-O), 4.92 (<< s », -CH -= c(, enol form),OH-resonance 
could not ~e observed. - Mass spectroscopy : m/e = 187 (M+ - CHa). CoH1sOaSI (202.3). Calcd. : C 53.43 H 8.97, Found : C 53.6 H 8.9. 
Neopenty/ ß-aminocrotonate 6a and trimethy{silyl-methy/ ß-amino-
crotonate 6b were prepared according lit. (24). 
3,3-DimethY/-butyl ß-aminocrotonate 7n. Ammonia is introduced 
at a water separator to a soJuUQrl of 23.2B g (0.125 mol) Sa and 0.4 g 
of ~-toluene sulfonic aci~ in 200 mL toluene at the boiling temperature 
untll no further water IS excreted. The reaction mixture is washed 
with a dilute aq:ueous solution of NaZC03 and then with water, and 
subsequently dned over Na2S0~, and the toluene distilled off at 
20 mm. T~e residue is fractionally distilled under vacuum. Yield 
19.1 g (82 %) of a colourless IH-NMR-spectroscopic pure product 
which crys!allizes in the distiJIation apparatus. The product is redistilled 
for analytlcal purposes. Bp. 92°Cfl mm, mp. 62°C. _ IH NMR 
(CnCla) : 8 0.91 (s, 9 H, C-CHa), 1.56 (m, centre of the AA'-part 
of an AA'XX' -system, 2 H, C-CHs-C), 1.86 (<< s », 3 H, ) C = t-CH
a
), 
4.10 (m, cent re of the XXJart of an AA'XX'-syst!lm, 2 H, C-CHz-O), 
4.50(<< s »,1 H, -CH = C",), NHz-resonancecouldnotbeobserved._ 
Mass speclroscopy : m/e (M+) == 185. CloHlONOz (1853) Calcd . 
64.83 H 10.34 N 7.56, Pound: 64.7 H 10.3 N 7.6. " .. 
~-Trimethylsi/yl-ethyl ß:aminocrotonate 7b. Analogous to tbe prepa-
ration of 7a by the reachon of BO.93 g (0.4 mol) Sb with ammonia in 
300 mL toluene under catalysis of 0.5 g of p-toluene sulfonic acid 
Yield 58.3 g (72,4 %), bp. B6'C/0.Ol mm, mp. 68°C. _ lH NMR 
(CDCI3) : 8 0.03 (s, 9 H, Si-CHa), 0.97 (m, centre of the AN-part of 
an AA'XX'-system, 2 H, Si-CHz-C), 1.90 (<< s »,3 H, )c = t-CH
a
), 
4.15 (m, centre of tbe XX'-part of an AA'XX'-system, 2 H, C-CHz-O), 
4.50 «< s »,1 H, -CH = C <), NHz-resonance could not beobserved. _ 
Mass spectroscopy : m/e (M+) = 201. C H NO SI (201 3) C I d 
C 53.69 H 9.51 N 6.96, Found : C 53.7 'H 19.5 ~ 6.9. . . ac. 
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Dlalkyl 2,6-dlmethyl-4-aryl-1 ,4-dlh;·drQPyritlillt'-3.5-dil'urhtJ.\·,l·latcs 
8n/8b - 12n/12b and 15n/lSb : 60 mmol alkyl ucetotlcctutc (4a. 4b. 
Sa, and Sb, resp.), 30 mmol of thc corrcsponding uldchydc R-CHO, 
and 3.3 mL concentrated ammonia, dissolvcd in 20 mL l,f ethanol 
(96 X), are heated to reflux for 20 hours. After cooling und (jf ncccssury) 
concentrating the solution, thc crystnllized product Is Illtcrcd off, 
recrystallized from the indicatcd solvent (Table 1). und dricd l" l'aellO 
(yields, physica! data and analytical data are givcn in Tublc 1). 
Di/leope/ltyl 2,6-dimethy/-4-( 3-m'mlphell,l'1 )-1, 4 .. dihydrapyridflle-3,5-
dical'boxy(ate 13a, bis( Il'imclhy(sil),l-meth.l'l) 2.6-dim"'h,l'/-4-( 3-lIitro-
phe/lY/)-} ,4-dlltydropyrldllle-3,5-dlcarbo.\:vlatc 13b, dilU.'I1PCIIIJ'/ 2,6-
dimethy/-4-( 2-/litropfre/ly/)-1 ,4-dihydropyridi/lc-3.5-dit'arhoxylare 14a 
and bis(trimethylsllyl-methyl) 2,6-dimetll.l·/-4-( 2-lIitroplu.'II.I'1 )-/,4-dihy-
dropyridi/le-3,5-dicarboxylate 14b were prepared according to Iit. (24). 
Neopell1yl trlmethylsllyl-lIIethyl 2,6-dimetlr,vI-4-( 3-lfirrop/I/!If.\·/)-1 ,4-
dihydropyridille-3,5-dlearbo:qlale 13c was prepared according 10 lit. 
(1). 
Dlalkyl 2,6-dimethYI-4-arY/-1 ,4-dihydroP.I'ridine-3.5-dicarbo.\:I'lales 16u 
16b - 24a/24b : A solution of 30 mmol alkyl ß-aminocrotonate (6n, 
6b, 7a and 7b, resp.) and 30 mmo! of the corresponding 2-aralkylidene-
acetoacetate R2CoH4-CH=C (COCH3) COOR in 20 mL of ethanol (96 %) is heated to reflux for 20 hours. After cooling and (jr ncccssary) 
coneentrating the solution, thc product crystaltlzed (In somc cases it 
is necessary to remove the ethanol comp!clcly und 10 substitute it 
by the recrystallization solvent. which is dcscribed in Tuble 2). The 
solid product is filtered off. recrystallizcd from the indicatcd solvent 
(Table 2), and dried ;11 vacuo (yields, physical dnla, and nnalytical 
data are given in Table 2). 
MEASUREMENT OF LIPOPHILICITY 
The relative Hpophilicity of the su bstances was measured by reversed-
phase thin-Iayer chromatography according to the methods described 
in lit. (32-35). Silanized silica gel plates [E. Merck, Darmstadt. F.R.G., 
5747 (60 Fm)] represented the stationary phase. The polar mobile 
phase consisted of a dioxane-acetone-water mixture (1 : 2 : 2). All 
compounds were dissolved in a mixture of methanol-chloroform 
(J : 1). 2-3 IJ.I of each SOlution were applied as a circular spot on the 
plate by a micropipette. The test substances and two control substances 
were ron from the starting line for about 1 hour at constant temperature 
(23 ~ O.S'C). After drying the plates, all test spots were detected by 
UV Irght at 254 nm. The experiments were repeated eight times. The 
RM-values were calculated by means of the experimental RF-values 
and the formula RM = log [(I/Rp) - 1]. Higher RM-values indicate 
compounds to be more lipophilie than those of lower RM"values. 
PHARMACOLOGY 
. 8a/8b - 24a/24b. and 13c were investigated with respect to the follow-
mg pharmacologlcal properties : 
1) Spasmolytic effect on tbe Ba++-stlmulated isolated guinea plg 
ileum (according to the method described in Ht. (21) ). 
. 2) Variation of the coronary sinus oxygen content in the anaesthe-!lze~ dog after Lv. administration (accordlng to the method described 
m ht. (21». 
3) Antihypertenslve effect on the renal-hypertensive rat after p.o. 
administration (according to the method described in lit. (21)). 
The in vitro pharmacological investigations were carried out under 
the light of a sodium vapour lamp. 
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